Postgrad LIVE! Study Fairs

Birmingham | Edinburgh | Liverpool | Sheffield | Southampton | Bristol

University of Bristol Featured PhD Programmes
University of Oxford Featured PhD Programmes
Coventry University Featured PhD Programmes
University of St Andrews Featured PhD Programmes
Max Planck Society Featured PhD Programmes
"cancer" AND "immunology"…×
10 miles

cancer immunology PhD Projects, Programs & Scholarships

We have 40 cancer immunology PhD Projects, Programs & Scholarships

  • "cancer" AND "immunology" ×
  • clear all
Order by 
Showing 1 to 10 of 40
  Machine Learning and Integrative Approaches in Immunology: Developing machine-learning and mathematical models to understand heterogeneity of response to personalised cancer immunotherapy
  Dr H Koohy, Prof V Cerundolo, Prof T Dong, Prof A Simmons
Application Deadline: 11 January 2019
Cancer immunology is an area of cancer research that is gaining tremendous momentum. However, responses to immunotherapy are heterogeneous and patient care could be substantially improved by better understanding of how and why responses to immunotherapeutic approaches vary in different patients.
  PhD studentship in oncolytic virotherapy and cancer immunology: Establishing a potent immuno-oncolytic virotherapy for colorectal cancer.
  Dr A Parker, Prof A Gallimore, Dr A Godkin
Application Deadline: 1 February 2019
An exciting, fully funded PhD studentship opportunity. working at the interface between oncolytic virotherapy and cancer immunotherapy to develop a refined, tumour targeted “immunovirotherapy” suitable for colorectal cancer treatment.
  Four Year Integrated PhDs in Cancer, Immunology, Infection and Biomedicine
 Four Year Integrated PhDs in Cancer, Immunology, Infection and Biomedicine. Research in. • The Cell Biology and Immunology of Cancer.
  Genomics of Inflammation and Cancer Immunology: inter-individual variation in response to checkpoint inhibitor therapy
  Dr B Fairfax
Application Deadline: 11 January 2019
We work on characterising inter-individual variation in human immune responses. Checkpoint inhibitor immunotherapy has revolutionised the management of multiple cancers, yet our understanding of how the response to these treatments diverges between patients is limited.
  MRC Precision Medicine DTP: Stromal transcriptomic signatures in prostate cancer metastasis and hormone therapy resistance
  Research Group: MRC Centre for Reproductive Health
  Dr B-Z Qian, Prof H Y Leung, Dr A Sims, Prof P Wiklund
Application Deadline: 7 January 2019
Background. A tremendous amount of cancer ‘-omics’ data have been generated with the intention to stratify patients for personalized diagnosis and treatment.
  Four-year funded PhDs in Translational Immunology, Inflammation and Cancer
Four-year funded PhDs in Translational Immunology, Inflammation and Cancer. The University of Southampton and Queen Mary University of London (QMUL) are Russell Group universities with world leading research programmes and are proud to offer Medical Research Council (MRC) funded studentships.
  Four-year funded PhDs in Translational Immunology, Inflammation and Cancer
Four-year funded PhDs in Translational Immunology, Inflammation and Cancer. The University of Southampton and Queen Mary University of London (QMUL) are Russell Group universities with world leading research programmes and are proud to offer Medical Research Council (MRC) funded studentships.
  ERK5 drives immune suppression in cancer
  Dr C Tournier, Dr K Finegan
Applications accepted all year round
The inflammatory microenvironment is arguably one of the most influential components of most, if not all, tumours (1).
  Regulation and function of cytotoxic lymphocytes
  Dr I. Voskoboinik, Prof J.A. Trapani
Applications accepted all year round
Cytotoxic lymphocytes recognize and kill cancerous and virus-infected cells through cytotoxic granule exocytosis pathway. Cytotoxic granules store a pore-forming protein, perforin, and serine proteases, granzymes.
  New mechanisms of PI3K-driven cancer development and alternative uses of PI3K-inhibitors in cancer
  Prof B Vanhaesebroeck, Dr P Tibarewal
Application Deadline: 14 December 2018
The PI3K/PTEN signalling axis is one of the most frequently aberrantly-activated pathways in cancer. PTEN is a tumour suppressor gene, the loss of which leads to PI3K-pathway over-activation.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2018
All rights reserved.